Amiodarone - Sonus Pharmaceuticals

Drug Profile

Amiodarone - Sonus Pharmaceuticals

Alternative Names: S 2646; Tocosol Amiodarone

Latest Information Update: 04 Apr 2008

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator Sonus Pharmaceuticals
  • Class Benzofurans; Class III antiarrhythmics; Heart failure therapies; Small molecules
  • Mechanism of Action Beta-adrenergic receptor antagonists; KATP channel inhibitors; Sodium channel antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Ventricular arrhythmias

Most Recent Events

  • 04 Apr 2008 Discontinued - Preclinical for Ventricular arrhythmias in USA (unspecified route)
  • 01 Jun 2005 No development reported - Preclinical for Ventricular arrhythmias in USA (unspecified route)
  • 15 Oct 2002 Preclinical trials in Ventricular arrhythmias in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top